Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic SyndromesGlobeNewsWire • 11/20/23
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/02/23
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023GlobeNewsWire • 10/19/23
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023GlobeNewsWire • 08/29/23
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/23
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia VeraGlobeNewsWire • 08/03/23
Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a BetZacks Investment Research • 07/17/23
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023GlobeNewsWire • 07/13/23
Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?Zacks Investment Research • 06/28/23
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin ResponseGlobeNewsWire • 06/26/23
Wall Street Analysts Believe Agios Pharmaceuticals (AGIO) Could Rally 39.16%: Here's is How to TradeZacks Investment Research • 06/12/23
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023GlobeNewsWire • 06/05/23
Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 05/30/23
Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?Zacks Investment Research • 05/25/23